Literature DB >> 23096173

Pseudolesion of the liver on gadoxetate disodium-enhanced MR images obtained after transarterial chemoembolization for hepatocellular carcinoma: clinicoradiologic correlation.

Yoshinobu Shinagawa1, Keiko Sakamoto, Ritsuko Fujimitsu, Mikiko Shimakura, Shin-ichi Kora, Koichi Takano, Kengo Yoshimitsu.   

Abstract

OBJECTIVE: The purpose of this study was to elucidate the clinicoradiologic characteristics of pseudolesions of the liver in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) as observed on gadoxetate disodium-enhanced MR images. A particular interest was correlation between the pseudolesion characteristics and TACE-MRI interval, during which sequential changes in pseudolesions may be revealed after TACE.
MATERIALS AND METHODS: Forty-eight patients with HCC who underwent gadoxetate disodium-enhanced MRI after TACE were retrospectively recruited. Pseudolesions were defined as areas of decreased signal intensity in treated areas on hepatocellular phase images that were confirmed to be nontumorous areas at follow-up. The prevalence and MRI features of pseudolesions were correlated with various clinical parameters, including TACE-MRI interval.
RESULTS: Pseudolesions were found in 14 patients (29%). Within 1 month of TACE, the prevalence of pseudolesions was 83%. All of the pseudolesions had arterial enhancement, mimicking residual HCC. After 1 month, the prevalence of pseudolesions decreased, and these pseudolesions tended to exhibit no abnormality in any sequence other than the hepatocellular phase. Results of multivariate analysis suggested that size of HCC (p < 0.0001), duration of postembolization syndrome (p = 0.012), and TACE-MRI interval (p = 0.038) are independent indicators of the presence of pseudolesions.
CONCLUSION: The prevalence and appearance of pseudolesions differ at different intervals from TACE. Radiologists need to recognize the clinicoradiologic characteristics to differentiate pseudolesions from true residual or recurrent HCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23096173     DOI: 10.2214/AJR.11.8204

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  5 in total

Review 1.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

2.  Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma.

Authors:  Yuko Nakamura; Tomoki Kimura; Toru Higaki; Yukiko Honda; Daisuke Komoto; Takuji Yamagami; Makoto Iida; Yasushi Nagata; Yohji Honda; Hiroshi Aikata; Kazuaki Chayama; Kazuo Awai
Journal:  Jpn J Radiol       Date:  2015-07-31       Impact factor: 2.374

3.  Effects of hypoxia-inducible factor-1α silencing on the proliferation of CBRH-7919 hepatoma cells.

Authors:  Lin-Feng Xu; Jia-Yan Ni; Hong-Liang Sun; Yao-Ting Chen; Yu-Dan Wu
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

4.  A feasibility study evaluating the relationship between dose and focal liver reaction in stereotactic ablative radiotherapy for liver cancer based on intensity change of Gd-EOB-DTPA-enhanced magnetic resonance images.

Authors:  Sang Hoon Jung; Jeong Il Yu; Hee Chul Park; Do Hoon Lim; Youngyih Han
Journal:  Radiat Oncol J       Date:  2016-03-30

5.  The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study.

Authors:  Youn Zoo Cho; So Yeon Park; Eun Hee Choi; Soon Koo Baik; Sang Ok Kwon; Young Ju Kim; Seung Hwan Cha; Moon Young Kim
Journal:  Clin Mol Hepatol       Date:  2015-06-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.